Paradigm
Paradigm Health operates an AI-powered clinical research platform that connects biopharma sponsors, 166 healthcare provider organizations, and patients to automate clinical trial matching, EHR-integrated data capture, and real-time FDA regulatory reporting, primarily in oncology.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Paradigm does
Paradigm Health is a U.S.-based healthcare technology company, founded in 2021 and headquartered in Columbus, Ohio, that operates an AI-powered clinical research platform connecting patients, healthcare provider organizations, and biopharma trial sponsors. The company has built the largest oncology research network in the United States, spanning 166 healthcare provider organizations with 2,100 care locations across 45 states — including 23 NCI-Designated Cancer Centers, 43 academic medical centers and health systems, and 123 community oncology practices — collectively reaching an estimated 70% of the U.S. cancer population and approximately 2.4 million patients following the December 2025 acquisition of Flatiron Health's Clinical Research Business. The platform serves 15 of the top 20 global biopharma companies with Phase I–III oncology trials and is the sole technology provider for the FDA's Real-Time Clinical Trials proof-of-concept studies.
The platform is composed of several integrated modules: an AI-native clinical trial matching engine built on large language models (including GPT-4) that reasons over structured EHR data and unstructured clinical notes, pathology reports, and molecular test results; an EHR-integrated eSource data capture module (eSource Casebook) that automates patient identification, enrollment, and EHR-to-database transfer with over 99% automated capture and a median 1.7-day transfer time; a Study Conduct platform for real-time safety and efficacy signal reporting to sponsors and the FDA; and SPIRE, a scalable platform for late-phase and post-approval pragmatic studies. The technology embeds directly into electronic health record environments — including Flatiron's OncoEMR via a multi-year strategic partnership — to integrate trial operations into routine clinical workflows. Compliance posture is anchored by third-party SOC 2 Type 2 and HIPAA attestations with unqualified opinions.
Paradigm generates revenue through enterprise platform agreements negotiated with biopharma sponsors and large healthcare provider organizations, structured as multi-year contracts covering trial feasibility, patient matching, site selection, EHR-integrated data collection, and regulatory reporting. Distribution combines direct enterprise sales with channel partnerships, notably Parexel for CRO-side integration, Fujitsu for the Japanese market, and Sheba Medical Center/ARC Innovation for the Israeli market. Total disclosed equity funding is approximately $281 million across a $203 million Series A (January 2023) and a $78 million Series B (December 2025), both led by ARCH Venture Partners.
Paradigm firmographics
Firmographics- Name
- Paradigm
- Legal name
- Paradigm Health, Inc.
- Website
- https://paradigmhealth.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Paradigm Health operates an AI-powered clinical research platform that connects biopharma sponsors, 166 healthcare provider organizations, and patients to automate clinical trial matching, EHR-integrated data capture, and real-time FDA regulatory reporting, primarily in oncology.
- Ownership category
- akta.pro rank
Paradigm industry classification
Industry- Product category
- Clinical Trial Technology
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
- akta.pro secondary industry
- Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
Keywords
Where Paradigm is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Paradigm business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform and Software Services to Sponsors and Providers: Paradigm Health provides its AI-powered clinical research platform to healthcare provider organizations (hospitals, oncology practices) and biopharma sponsors. Revenue appears to come from platform subscriptions and service fees for clinical trial execution support. The company integrates its technology into provider workflows and provides end-to-end study conduct services, including site selection, patient recruitment, feasibility, and data collection.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform agreements — pricing not publicly disclosed |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Paradigm product offering
Product offeringCore offering
Paradigm Health operates an AI-powered clinical research platform that connects patients, healthcare providers, and trial sponsors to automate and streamline clinical trial execution. The platform integrates directly with electronic health records (EHRs) to perform AI-driven patient matching, site feasibility analysis, EHR-to-database data capture, and real-time safety/efficacy signal reporting for sponsors and the FDA. It serves a network of 166 healthcare provider organizations across 45 U.S. states and supports 15 of the top 20 global biopharma companies running Phase I-III oncology trials and late-phase pragmatic studies.
Product overview
Paradigm Health offers an AI-powered, end-to-end clinical research platform that connects patients, providers, and trial sponsors. The unified platform combines multiple integrated solutions including: the core Paradigm Platform for clinical trial orchestration; Study Conduct / eSource Casebook for EHR-integrated real-time data capture and FDA collaboration; SPIRE (Scalable Platform for Integrated Research & Evidence) for late-phase/post-approval evidence generation; AI-enabled Clinical Trial Matching for patient identification and enrollment; Protocol Optimization for feasibility and site selection; and a Provider Network of 166+ healthcare organizations across 45 states. The platform supports Phase I-III oncology trials for 15 of the top 20 global pharmaceutical companies and operates the largest oncology research network in the U.S.
Differentiator
Problem solved
Functional benefit
Brands
- SPIRE: Scalable Platform for Integrated Research & Evidence - an end-to-end, technology-enabled alternative to traditional CRO-led approaches for prospective, pragmatic studies, particularly for peri-approval and post-approval products with established safety profiles
- eSource Casebook
- Trial Design Service
Products and services
- Paradigm Health Platform End-to-end AI-powered clinical research platform that connects patients, healthcare providers, and trial sponsors, automating feasibility analysis, patient matching, site selection, enrollment, and real-time data capture across a nationwide network of 166 healthcare provider organizations in 45 U.S. states.
- Study Conduct Platform Real-time FDA-aligned study conduct solution that captures data directly from EHRs, algorithmically evaluates FDA-defined data points, and transmits critical safety and efficacy signals to sponsors and the FDA for ongoing regulatory review.
- eSource Casebook EHR-integrated data capture solution (formerly Clinical Pipe) that embeds research directly into the electronic health record environment, automating patient identification, enrollment, and data collection within routine clinical workflows with over 99% automated EHR-to-database transfer.
- SPIRE (Scalable Platform for Integrated Research & Evidence) End-to-end technology-enabled model for post-approval and late-stage clinical studies, combining pragmatic study design, streamlined patient recruitment, and EHR-integrated data capture across research-ready community and academic sites across 46 states.
- AI Clinical Trial Matching AI-native clinical trial matching solution using large language models (including GPT-4) to match patients to trials by reasoning over unstructured clinical notes, eligibility criteria, and structured EHR data, achieving 31-87% reduction in screening volumes and 10% higher accuracy than state-of-the-art ML models.
- Protocol Optimization & Site Selection Protocol optimization and feasibility assessment tool that enables sponsors and sites to evaluate clinical trial opportunities, verify alignment of inclusion/exclusion criteria with local patient populations, and select optimal sites based on care patterns and capabilities.
Quantifiable outcome
- 45% increase in clinical trial patient enrollment over two years at partner site
- +7 more outcomes
Companies that use Paradigm
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Paradigm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability9 records
Feature5 records
Paradigm partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, minor and major.
- U.S. Food & Drug Administration (FDA)coreParadigm Health announced a landmark research collaboration with the FDA to accelerate clinical trial execution and regulatory review using its AI-powered Study Conduct platform for real-time data collection and reporting. The FDA is operationalizing proof-of-concept studies with AstraZeneca (Phase 2 TRAVERSE) and Amgen (Phase 1b STREAM-SCLC) using Paradigm's SPIRE platform, marking the first real-time clinical trial monitoring system implemented by the agency.
- Flatiron Health (a Roche affiliate)coreParadigm Health acquired Flatiron Health's Clinical Research Business and established a multi-year strategic partnership. The transaction expanded Paradigm's network to over 25 academic medical centers and nearly 100 community oncology practices, reaching 2.4 million patients. Paradigm Health will integrate its solutions into Flatiron's OncoEMR platform (used by over 4,500 providers at 1,000+ community-based cancer care locations) and provide clinical research support to all Flatiron OncoEMR customers. The partnership creates the largest oncology research network in the United States.
- CEO Roundtable on Cancer / PACT CollectiveminorParadigm Health partnered with the CEO Roundtable on Cancer to launch the PACT Collective, aimed at expanding clinical trial access and diversity in cancer research.
- ParexelmajorParexel and Paradigm Health partnered to expand access and efficiency in clinical trials. Parexel incorporated Paradigm's AI-enabled clinical trial infrastructure into its service offerings, with Paradigm participating in Parexel's strategic partnerships alongside Weave Bio and Palantir under the ParexelAI initiative.
- Sheba Medical Center / ARC Innovation (Israel)majorStrategic partnership to transform clinical trials in Israel using Paradigm's AI-driven platform. The collaboration aims to scale the platform at Sheba and expand it to affiliated clinics throughout Israel, with ARC intending to expand the platform to its global ecosystem of hospitals. The Riva Koschitzky Oncology Clinical Research Unit at Sheba will serve as the lead site.
- FujitsumajorFujitsu formed a strategic partnership with Paradigm Health to attract global clinical trials to Japan and tackle the 'drug loss' issue. Fujitsu combines Paradigm's clinical trial platform with its Healthy Living Platform and Kozuchi AI service to facilitate clinical trial planning and implementation across Japanese medical institutions. Fujitsu launched Patient-centric Clinical Trials, a new service using its proprietary LLM for automated clinical trial document creation.
- Bristol-Myers SquibbmajorA strategic partnership was announced with Bristol-Myers Squibb as one of Paradigm's early biopharma partnerships following the company's emergence from stealth.
Scale indicators8 records
Recent moves11 records
Expansion highlights6 records
Paradigm competitors and assessment
Company assessmentDirect peers
- Medidata (Dassault Systèmes): Medidata is a leading provider of clinical trial technology including EDC, CTMS, eCOA, and patient cloud platforms. It is the most direct competitor to Paradigm in clinical trial informatics, serving many of the same top 20 global biopharma sponsors with an established enterprise install base.
- Veeva Systems: Veeva offers a clinical trial suite (Vault CTMS, Vault EDC, Vault CDB) that competes with Paradigm's platform across the biopharma sponsor workflow. Veeva serves most of the same top 20 biopharma companies and represents the most prominent cloud-based incumbent in life sciences clinical operations.
- Science 37: Science 37 is a direct competitor in decentralized and technology-enabled clinical trials, with a metadata-driven platform for remote patient participation. Paradigm's CFO Jay Trepanier was previously CFO of Science 37, illustrating the close overlap in operating model and customer segment.
- Elligo Health Research: Elligo provides a research-ready site network and technology platform enabling community and rural providers to run clinical trials, with a similar GTM to Paradigm's community oncology expansion. Both companies target bringing trials closer to routine care delivery.
Broad incumbents
- Oracle Health Sciences (Clinical One): Oracle's Clinical One platform unifies EDC, RTSM, clinical trial supply, and analytics for biopharma sponsors. As a broad incumbent, Oracle competes with Paradigm in eSource and trial data collection, with deep enterprise penetration from its prior InForm and Siebel CTMS franchises.
- IQVIA: IQVIA is the largest global CRO and life sciences technology provider, with significant clinical trial technology assets (e.g., E360, OCE, Patient Engagement) and the scale to bundle competing offerings to the same top 20 biopharma clients that Paradigm serves.
- ICON plc: ICON is a global CRO formed from the PRA Health Sciences merger, where Paradigm's CEO previously served. ICON competes across clinical trial services and increasingly technology-enabled trial execution, overlapping with Paradigm's SPIRE-style late-phase model.
Emerging players
- Tempus AI: Tempus AI operates a molecular data and AI platform increasingly used for clinical trial matching and patient identification in oncology. It overlaps with Paradigm's AI-native matching and biomarker-driven enrollment, and competes for the same biopharma R&D and site ecosystem.
- Advarra: Advarra provides technology and services for clinical research sites, sponsors, and IRBs, including CTMS, eRegulatory, and feasibility tools. It overlaps with Paradigm's site-facing platform modules and serves a similar provider customer base.
Others
- Flatiron Health: Flatiron Health (a Roche affiliate) sold its Clinical Research Business to Paradigm in December 2025 and entered a multi-year strategic partnership. Flatiron remains a peer in oncology EHR data and research operations, but is now an integrated partner rather than direct competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Paradigm social profiles
Digital presenceParadigm compliance and trust
Trust signalCompliance2 records
Paradigm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paradigm leadership team
Management profileNumber of profiles
Profiles8 records
Paradigm subsidiaries and ownership
Company hierarchySubsidiaries1 record
Paradigm funding detail
Funding detailFunding overview
Funding rounds2 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paradigm M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paradigm
What does Paradigm do?
Paradigm Health operates an AI-powered clinical research platform that connects patients, healthcare providers, and trial sponsors to automate and streamline clinical trial execution. The platform integrates directly with electronic health records (EHRs) to perform AI-driven patient matching, site feasibility analysis, EHR-to-database data capture, and real-time safety/efficacy signal reporting for sponsors and the FDA. It serves a network of 166 healthcare provider organizations across 45 U.S. states and supports 15 of the top 20 global biopharma companies running Phase I-III oncology trials and late-phase pragmatic studies.
Is Paradigm a public or private company?
Paradigm is a private company. It is classified as venture growth investor backed and is currently operating.
When was Paradigm founded?
Paradigm was founded in 2021. It employs 101 to 250 people.
Where is Paradigm based?
Paradigm is headquartered in New York, United States, in the North America region.
How does Paradigm make money?
One revenue line is on record: platform and Software Services to Sponsors and Providers.
Who are Paradigm's main competitors?
Direct peers on record are Medidata (Dassault Systèmes), Veeva Systems, Science 37 and Elligo Health Research. Broad incumbents are Oracle Health Sciences (Clinical One), IQVIA and ICON plc. Emerging players are Tempus AI and Advarra. Flatiron Health is listed as an others.
Does Paradigm have an API?
No public API is recorded for Paradigm.
What industry is Paradigm in?
Paradigm's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 54151 and its SIC code is 7372.